Intercytex Group plc (LSE: ICX) ("Intercytex") today announces temporary suspension of trading of its shares on AIM

Suspension of trading on AIM


2nd September 2009

Intercytex Group plc (LSE: ICX) ("Intercytex") today announces temporary suspension of trading of its shares on AIM. As a result of the ongoing divestment process, the Company will not be in a position to release interim financial results before 30 September 2009, and will therefore be suspended from trading until such results are released.

The Company remains in advanced discussions with a number of parties to divest certain business assets, and will continue to update shareholders on both the progress of the strategic review and the potential timing of release of interim financial results.

Enquiries

For more information, contact:

Intercytex Group plc  
Nick Higgins, Chief Executive Officer Tel: 0161 904 4500
Max Herrmann, Chief Financial Officer  
   
Financial Dynamics  
Jonathan Birt Tel: 0207 269 7205
   
Piper Jaffray Ltd  
Will Carnwath Tel: 0203 142 8700

 

Intercytex' shares trade on AIM, a market of the London Stock Exchange, under the ticker symbol ICX.L.

Additional information on the Company can be found at www.intercytex.com

Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management's best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release. The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings.

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.